Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - omalizumab 150 mg/ml;   - solution for injection - 75 mg/0.5ml - active: omalizumab 150 mg/ml   excipient: arginine hydrochloride histidine histidine hydrochloride monohydrate polysorbate 20 water for injection - xolair (omalizumab) is indicated for the reduction of asthma exacerbations and control of asthma symptoms when given as add-on therapy for adult and adolescent patients, 6 years and older, with severe persistent allergic asthma who have ige greater than or equal to 30 iu/ml, a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.

Singapur - angleščina - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - omalizumab - injection, powder, lyophilized, for solution - 150mg - omalizumab 150mg

Singapur - angleščina - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - omalizumab - injection, powder, lyophilized, for solution - 75mg - omalizumab 75mg

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - omalizumab 150mg - powder for injection with diluent - 150 mg - active: omalizumab 150mg excipient: histidine histidine hydrochloride polysorbate 20 sucrose water for injection - xolair is indicated for the reduction of asthma exacerbations and control of asthma symptoms when given as add-on therapy for adult and adolescent patients, 6 years and older, with severe persistent allergic asthma who have ige > 30 iu/ml, a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled iwth inhaled corticosteroids.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - omalizumab 75mg - injection with diluent - 75 mg - active: omalizumab 75mg excipient: histidine histidine hydrochloride polysorbate 20 sucrose water for injection - xolair is indicated for the reduction of asthma exacerbations and control of asthma symptoms when given as add-on therapy for adult and adolescent patients, 6 years and older, with severe persistent allergic asthma who have ige > 30 iu/ml, a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled iwth inhaled corticosteroids.

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - omalizumab - solution for injection - 150mg/1ml

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - omalizumab - solution for injection - 150mg/1ml

Kanada - angleščina - Health Canada

novartis pharmaceuticals canada inc - omalizumab - powder for solution - 150mg - omalizumab 150mg - respiratory agents, miscellaneous

Kanada - angleščina - Health Canada

novartis pharmaceuticals canada inc - omalizumab - solution - 75mg - omalizumab 75mg - respiratory agents, miscellaneous

Kanada - angleščina - Health Canada

novartis pharmaceuticals canada inc - omalizumab - solution - 150mg - omalizumab 150mg - respiratory agents, miscellaneous